University Hospital of Lille
Welcome,         Profile    Billing    Logout  
 104 Trials 
53 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mathurin, Philippe
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
FRESH, NCT05639543 / 2022-001639-10: FXR Effect on Severe Alcohol-Associated Hepatitis () Study

Recruiting
2
50
Europe, US
INT-787, Placebo
Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc.
Alcohol Associated Hepatitis
12/24
03/25
STARLIGHT, NCT06613698: A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease

Not yet recruiting
2
393
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline
Liver Diseases, Alcoholic
12/26
03/27
DERAMBURE, Philippe
TrustTSC, NCT05323734 / 2021-003441-38: Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy

Completed
3
128
Europe, Canada, US, RoW
Ganaxalone, Placebo
Marinus Pharmaceuticals, Marinus Pharmaceuticals Inc., Marinus Pharmaceuticals, Inc.
Tuberous Sclerosis Complex
09/24
10/24
CENOR, NCT05747001: This is a Retrospective Study on the Use of CENOBAMATE as Adjunctive Treatment in Patients Suffering From Epilepsy in Early Access Program in Germany, France and UK

Completed
N/A
319
Europe
Aziende Chimiche Riunite Angelini Francesco S.p.A, Hippocrates Research
Focal Onset Seizure, Epilepsy
09/23
09/23
GALVANI GS-3, NCT06334952: Efficacy of Personnalized Transcranial Direct Current Electrical Stimulation (tDCS) in Drug-resistant Epileptic

Recruiting
N/A
60
Europe
transcranial direct current stimulation, Research MRI, EEG
Assistance Publique Hopitaux De Marseille, CRMBM-CEMEREM, Institut National de la Santé Et de la Recherche Médicale, France - LTSI, Neuroelectrics Corporation
Epilepsy, Drug Resistant Epilepsy
12/26
11/27
Vantyghem, Marie-Christine
NCT06484868: Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

Recruiting
4
12
Europe
Metreleptin
Amryt Pharma
Partial Lipodystrophy
09/27
09/27
ACSPIRE, NCT05436639 / 2022-000748-32: SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

Active, not recruiting
2
30
Europe, US
SPI-62 dose
Sparrow Pharmaceuticals, Sparrow Pharmaceuticals, Inc.
Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome, ACTH-Independent Adrenal Cushing Syndrome, Somatic
12/24
12/25
LINC6, NCT05382156: Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

Active, not recruiting
N/A
206
Europe, US
Osilodrostat, Isturisa
RECORDATI GROUP
Endogenous Cushing's Syndrome
06/27
08/27
MEASuRE, NCT02325674: Metreleptin Effectiveness And Safety Registry

Recruiting
N/A
100
Europe, US
Metreleptin
Aegerion Pharmaceuticals, Inc.
Generalised Lipodystrophy, Partial Lipodystrophy
10/31
10/31
Belle, Eric Van
NCT05437900: INSIGHTFUL-FFR Clinical Trial

Recruiting
4
2500
Europe, RoW
Pressure Microcatheter guided strategy - PIOS MC, Pressure Wire guided strategy - PIOS - PW, Pressure Microcatheter guided strategy - Standard of care, Pressure Wire guided strategy - Standard of care
CoreAalst BV, Insight Lifetech Co., Ltd.
Coronary Artery Disease, Acute Coronary Syndrome
06/26
06/30
RESTO, NCT04268875: Morphological Parameters of In-stent RESTenosis Assessed and Identified by OCT

Completed
N/A
307
Europe
Optical Coherence Tomography (OCT)
University Hospital, Clermont-Ferrand, Abbott, Corelab ISIT
In-stent Restenosis
12/22
12/22
PiCSO-AMI-V, NCT04958421: A Study to Evaluate Safety and Feasibility of PiCSO Therapy in Patients With ST Elevation Inferior Wall Myocardial Infarction.

Terminated
N/A
25
Europe
PiCSO Impulse System
Miracor Medical SA
STEMI - ST Elevation Myocardial Infarction, Inferior Wall Myocardial Infarction
02/23
02/23
NCT05235568: VALVOSOFT® Pivotal Study

Completed
N/A
60
Europe
VALVOSFT intervention
Cardiawave SA, QbD Clinical
Aortic Valve Calcification, Aortic Valve Stenosis
08/23
07/24
NCT03424941: The TransCatheter Valve and Vessels Trial

Completed
N/A
172
Europe
FFR-guided PCI and TAVI, CABG and SAVR
Maatschap Cardiologie Zwolle, Medtronic
Aortic Stenosis, Multi Vessel Coronary Artery Disease, TAVI, CABG, PCI, Fractional Flow Reserve
06/24
06/24
NCT02710435: REDUCER-I: An Observational Study of the Neovasc Reducer™ System

Active, not recruiting
N/A
400
Europe
Reducer System, Reducer
Neovasc Inc., Shockwave Medical, Inc.
Angina Pectoris, Angina Pectoris, Stable, Chronic Stable Angina
11/23
12/28
HighFLO, NCT04888247: Study - HighLife Trans-septal Mitral Valve Replacement (TSMVR) Feasibility Study of the Open Cell CLARITY Valve

Recruiting
N/A
30
Europe, RoW
CLARITY
HighLife SAS
Mitral Regurgitation
12/25
02/31
LANDMARK, NCT04275726: Trial: a Randomised Controlled Trial of Myval THV

Recruiting
N/A
768
Europe, RoW
Myval THV Series, Myval/Myval Inception THVs or any subsequent advanced version commercially available at the study site., Contemporary Valves (Sapien THV Series and Evolut THV Series), Sapien THV Series (Sapien 3/Sapien 3 Ultra THVs) and Evolut THV Series (Evolut R/Evolut PRO THVs ) or any subsequent advanced version commercially available at the study site.
Meril Life Sciences Pvt. Ltd.
Aortic Valve Stenosis
03/24
12/33
NCT04029363: Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk

Recruiting
N/A
120
Europe, RoW
HighLife Transcatheter Mitral Valve Replacement
HighLife SAS, ICON plc
Mitral Regurgitation
03/25
06/30
FAST III, NCT04931771: Fractional Flow Reserve or 3D-Quantitative-Coronary-Angiography Based Vessel-FFR Guided Revascularization

Recruiting
N/A
2228
Europe
vFFR guided revascularization, FFR guided revascularization
ECRI bv, Siemens Healthineers AG, Pie Medical Imaging
Coronary Artery Disease
05/25
05/25
NCT05601453: The ReTAVI Prospective Observational Registry

Recruiting
N/A
150
Europe, Canada, RoW
Elective redo transcatheter aortic valve implantation (redo-TAVI), redo-TAVI, redo-TAVR, Valve-in-Valve (ViV), TAV-in-TAV, TAVR-in-TAVR, Revalve
Institut für Pharmakologie und Präventive Medizin, Edwards Lifesciences
Structural Valve Deterioration, Structural Valve Degeneration, Symptomatic Patients Who Have Had Transcatheter Heart Valve (THV) Failure, Prosthetic Valve Malfunction, Prosthesis Failure
09/25
12/26
MITRA-HR, NCT03271762: Multicentre Study of MITRACLIP® Transcatheter Mitral Valve Repair in Patients With Severe Primary Mitral Regurgitation Eligible for High-risk Surgery

Recruiting
N/A
330
Europe, RoW
percutaneous mitral valve repair with MITRACLIP NT, MITRACLIP NTR/XTR, MITRACLIP G4NT/XT, MITRACLIP G4NTW/XTW, MITRACLIP, cardiac surgery
Nantes University Hospital, Ministère de la Santé, Abbott
Mitral Regurgitation
03/27
05/28
PEREZ, Thierry
OSCIVARI, NCT04087590: Impact of Inhaled PT003 on Complexity and Variability of Tidal Breathing and Oscillatory Mechanics in Stable COPD Patient

Recruiting
2
35
Europe
Formoterol-glycopyrronium co suspension (PT003)
University Hospital, Lille, AstraZeneca
Copd
02/23
02/23
VARI-OSCIL, NCT06110403: Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness

Recruiting
1/2
35
Europe
TRIXEO AEROSPHERE
University Hospital, Lille, AstraZeneca
Copd
09/25
09/25
mariette, christophe
PROBIOCOL, NCT02121743: Use of a Biological Mesh (StratticeTM) for the Prevention of Parastomal Hernia After Colorectal Surgery With Colostomy

Active, not recruiting
N/A
80
Europe
strattice, No strattice
Centre Hospitalier Universitaire, Amiens, LifeCell
Parastomal Hernia, Terminal Colostomy
12/18
12/23
Adenis, Antoine
NEONIPIGA, NCT04006262: Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.

Checkmark Data from NEONIPIGA trial of nivolumab/ipilimumab neoadjuvant therapy in dMMR/MSI-H gastric or gastroesophageal junction adenocarcinoma
Aug 2022 - Aug 2022: Data from NEONIPIGA trial of nivolumab/ipilimumab neoadjuvant therapy in dMMR/MSI-H gastric or gastroesophageal junction adenocarcinoma
Recruiting
2
32
Europe
Nivolumab 10 MG/ML, Opdivo, Ipilimumab 200 MG in 40 ML Injection, Yervoy
GERCOR - Multidisciplinary Oncology Cooperative Group, Bristol-Myers Squibb
Localized Oesogastric Adenocarcimona, MSI and or dMMR
06/24
06/24
REGOMUNE, NCT03475953 / 2016-005175-27: A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

Recruiting
1/2
747
Europe
Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib, Phase 2 : Avelumab, Phase 2: low-dose Regorafenib
Institut Bergonié, Bayer, Merck KGaA, Darmstadt, Germany
Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma, Biliary Tract Cancer, Hepatocellular Carcinoma, Soft-tissue Sarcoma, Thyroid Cancer, Gastro-enteropancreatic Neuroendocrine Tumor, Non-small Cell Lung Cancer, Solid Tumor, Adult, Urothelial Carcinoma, HPV-Related Carcinoma, Triple Negative Breast Cancer, Renal Carcinoma, Mesotheliomas Pleural
12/24
12/25
Rollin-Sillaire, Adeline
DIAN-TU-002, NCT06647498: A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Recruiting
2/3
280
Europe, Canada, US, RoW
Remternetug, LY3372993, Matching Placebo (Remternetug)
Washington University School of Medicine, Alzheimer's Association, Eli Lilly and Company, National Institute on Aging (NIA), GHR Foundation, Private Donors
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
03/34
08/34
DIAN-TU, NCT05552157: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Recruiting
2/3
280
Europe, Canada, US, RoW
Remternetug (SC), Matching Placebo (Remternetug)
Washington University School of Medicine, Alzheimer's Association, Eli Lilly and Company, National Institute on Aging (NIA)
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
03/34
08/34
MACKOWIAK, Marie-Anne
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
PROGRESS-AD, NCT06079190: Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

Recruiting
2
282
Europe, Canada, US, RoW
GSK4527226, Placebo
GlaxoSmithKline, Alector Inc.
Alzheimer's Disease
12/26
02/29
DEFEBVRE, Luc
NCT04265209 / 2019-000247-27: [18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor

Recruiting
3
152
Europe
SPECT, PET
Zionexa
Parkinson Disease, Essential Tremor
09/24
12/24
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Active, not recruiting
2/3
110
Europe, US
AMX0035, Placebo
Amylyx Pharmaceuticals Inc.
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
04/26
11/29
NCT04691661: Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease

Recruiting
2
40
Europe
Radotinib HCl 50 mg, Radotinib, IY5511, Placebo
Il-Yang Pharm. Co., Ltd.
Parkinson Disease
12/25
12/26
PIMPARK, NCT03947216: Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

Completed
2
117
Europe
Active drug: pimavanserin 17mg (2 strength tablets), Placebo: 2 tablets containing same excipients except active compound, Assessment of severity of ICD (impulse control disorders), Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors, Assessment of quality of life, Assessment of depression, Assessment of cognition, Assessment of severity of Parkinson Disease, Blood analysis, Cardiac monitoring
University Hospital, Strasbourg, France, NS-PARK, EUCLID Clinical Trial Platform, F-CRIN, ACADIA Pharmaceuticals Inc.
Parkinson Disease
04/24
06/24
VERMERSCH, Patrick
MASIMS, NCT05441488 / 2021-000639-30: Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis

Recruiting
3
800
Europe, RoW
Placebo, Placebo Oral Tablet, Masitinib (4.5), AB1010
AB Science
Progressive Multiple Sclerosis
12/25
12/25
LOUVET, Alexandre
ProPILARifax, NCT03069131: Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites

Completed
3
160
Europe
Rifaximin, Placebo
Centre Hospitalier Universitaire de Besancon, Alfasigma S.p.A., LC2 PHARMA
Cirrhosis, Ascites, Peritonitis
06/22
03/23
NCT04950127 / 2021-000007-21: Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

Active, not recruiting
3
238
Europe, Canada, Japan, US, RoW
Linerixibat, Placebo
GlaxoSmithKline
Pruritus
10/24
01/25
LLSAT, NCT04167358 / 2019-003158-10: Linerixibat Long-term Safety, and Tolerability Study

Recruiting
3
251
Europe, Canada, Japan, US, RoW
Linerixibat
GlaxoSmithKline, GlaxoSmithKline LLC, GlaxoSmithKline Research & Development Limited
Cholestasis
02/27
02/27
PACIFIC, NCT05525520 / 2021-002526-25: Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

Completed
2
62
Europe, Canada, US, RoW
EP547, Placebo
Escient Pharmaceuticals, Inc, Escient Pharmaceuticals, Inc.
Pruritus
07/24
09/24
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
NCT04594694 / 2018-002575-17: Study of OCA in Combination with BZF Evaluating Efficacy, Safety, and Tolerability in Participants with PBC

Active, not recruiting
2
72
Europe, RoW
Obeticholic acid, Bezafibrate 200 MG, OCA Placebo, Bezafibrate 200 mg Placebo, Bezafibrate 400 MG, Bezafibrate 400 mg Placebo, OCA, Bezafibrate
Intercept Pharmaceuticals
Primary Biliary Cholangitis
10/25
10/25
PASQUIER, Florence
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
DIAN-TU, NCT01760005 / 2013-000307-17: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol -001

Checkmark From DIAN-TU trial
Feb 2020 - Feb 2020: From DIAN-TU trial
Checkmark Top-line data from DIAN-TU trial in rare inherited form of Alzheimer's disease
Feb 2020 - Feb 2020: Top-line data from DIAN-TU trial in rare inherited form of Alzheimer's disease
Checkmark DIAN TU: N=210
More
Recruiting
2/3
490
Europe, Canada, Japan, US, RoW
Gantenerumab, RO4909832, Solanezumab, LY2062430, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab), E2814, Lecanemab, BAN2401, Matching Placebo (E2814)
Washington University School of Medicine, Eli Lilly and Company, Hoffmann-La Roche, Alzheimer's Association, National Institute on Aging (NIA), Avid Radiopharmaceuticals, Accelerating Medicines Partnership (AMP), Eisai Inc., Janssen, LP
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
04/28
07/28
DIAN-TU, NCT05552157: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Recruiting
2/3
280
Europe, Canada, US, RoW
Remternetug (SC), Matching Placebo (Remternetug)
Washington University School of Medicine, Alzheimer's Association, Eli Lilly and Company, National Institute on Aging (NIA)
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
03/34
08/34
NCT04993755 / 2021-002251-11: A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

Active, not recruiting
2a
42
Europe, US
TPN-101, 400 mg/day, Placebo
Transposon Therapeutics, Inc., Transposon Therapeutics, Inc
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
09/23
09/23
Piessen, Guillaume
NEONIPIGA, NCT04006262: Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.

Checkmark Data from NEONIPIGA trial of nivolumab/ipilimumab neoadjuvant therapy in dMMR/MSI-H gastric or gastroesophageal junction adenocarcinoma
Aug 2022 - Aug 2022: Data from NEONIPIGA trial of nivolumab/ipilimumab neoadjuvant therapy in dMMR/MSI-H gastric or gastroesophageal junction adenocarcinoma
Recruiting
2
32
Europe
Nivolumab 10 MG/ML, Opdivo, Ipilimumab 200 MG in 40 ML Injection, Yervoy
GERCOR - Multidisciplinary Oncology Cooperative Group, Bristol-Myers Squibb
Localized Oesogastric Adenocarcimona, MSI and or dMMR
06/24
06/24
Endeavor-1, NCT06523374: A Study of Barrett's Esophagus Patients to Investigate Quality of Life and Fear of Cancer, and Optimize a Risk Model Based on Biomarkers and New Technologies to Better Predict the Development of Cancer

Not yet recruiting
N/A
50
Europe
Endoscopic brush cytology
University Hospital, Antwerp, Karolinska Institutet, Universal Diagnostics, Amsterdam UMC, Radboud University Medical Center, AZ Delta, Centre Hospitalier Universitaire de Liege, University of Leipzig, IRCCS Ospedale San Raffaele, Karolinska University Hospital, University of Dublin, Trinity College, Heinrich-Heine University, Duesseldorf, GZA Ziekenhuizen Campus Sint-Augustinus, University Hospital, Ghent, Rigshospitalet, Denmark, Universitätsklinikum Leipzig, St. James's Hospital, Ireland
Barrett's Esophagus, Esophageal Adenocarcinoma
11/25
11/26
Gueorguieva, Iva
SURMOUNT-ADOLESCENTS-2, NCT06439277: A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities

Recruiting
3
300
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Weight Gain
05/27
06/27
JEUNE, Florence LE
NCT04265209 / 2019-000247-27: [18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor

Recruiting
3
152
Europe
SPECT, PET
Zionexa
Parkinson Disease, Essential Tremor
09/24
12/24
PIGEYRE, MARIE
METRE-PL, NCT05164341: Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with PL

Recruiting
3
65
Europe, Canada, US, RoW
metreleptin, Placebo
Amryt Pharma
Partial Lipodystrophy
06/25
01/26
CHAHLA, Wadih ABOU
ALLTogether1, NCT04307576 / 2018-001795-38: A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

Recruiting
3
6430
Europe, RoW
Omitted Doxorubicin, Omitted Vincristine+Dexamethasone pulses, Inotuzumab Ozogamicin+Standard Maintenance Therapy, Besponsa+Maintenance Therapy, Imatinib, 6-tioguanine+Standard Maintenance Therapy, Blinatumomab, Blincyto
Mats Heyman, The Swedish Research Council, The Swedish Childhood Cancer Foundation, Pfizer, Servier, NordForsk, Aamu Pediatric Cancer Foundation, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Clinical Trial Center North (CTC North GmbH & Co. KG), Belgium Health Care Knowledge Centre, Karolinska Institutet, Cancer Research UK, Fundação Rui Osório de Castro, Acreditar - Associação de Pais e Amigos das Crianças com Cancro, Grupo Português De Leucemias Pediátricas, Amgen, Nova Laboratories Limited, Danish Child Cancer Foundation, Danish Cancer Society, The Novo Nordic Foundation, Assistance Publique - Hôpitaux de Paris, Direction Générale de l'Offre de Soins
Leukemia, Acute Lymphoblastic
06/27
06/32
Branche, Julien
NCT05353985 / 2020-005438-14: A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

Completed
2
153
Europe, Canada, US
TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar
Takeda
Celiac Disease
11/24
11/24

Download Options